Christopher Anzalone - Dec 16, 2022 Form 4 Insider Report for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Role
Chief Executive Officer, Director
Signature
/s/Christopher Anzalone
Stock symbol
ARWR
Transactions as of
Dec 16, 2022
Transactions value $
$0
Form type
4
Date filed
12/20/2022, 06:09 PM
Previous filing
Sep 29, 2022
Next filing
May 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARWR Common Stock Award $0 +18.4K +0.53% $0.00 3.49M Dec 16, 2022 Direct F1
transaction ARWR Common Stock Award $0 +234K +6.71% $0.00 3.72M Dec 20, 2022 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of stock which vested on the date of issuance.
F2 Includes 93,610 shares underlying restricted stock units, which will vest in four equal installments, with a commencement date of 12/20/22. Includes 140,415 underlying restricted stock units, that may be earned based on the achievement of certain performance and/or market-based goals. If the goals are not met within the required time periods, the awards will be forfeited in part of in whole.
F3 Includes a total of 1,789,697 shares underlying restricted stock units that may be earned based on the achievement of certain performance and/or market-based goals. If the goals are not met within the required time periods, the awards will be forfeited in part or in whole.